- This event has passed.
Path to a COVID-19 Vaccine
December 11, 2020
When COVID-19 vaccine is finally ready, will the world be?
Vaccine development in general on average takes 8-15 years. So even the talk about having a vaccine in the next 12-18 months since the pandemic started is breathtakingly optimistic.
Considering the challenges and complications around developing a coronavirus vaccine, when COVID-19 vaccine is finally ready, will the world be? How safe and efficient will this vaccine be?
Join us in a panel discussion with life sciences experts from academia and venture capital to hear how the industry is trying to work towards a solution and achieve a shared global goal of identifying a potential cure for COVID-19. Watch replay below.
Moderated by Hemai Parthasarathy from Breakout Ventures, speakers include John Lewis from University of Alberta, Una Ryan from Golden Seeds and Jenny Yip from Adjuvant Capital.
Topics of discussion include
- What are the different type of approaches for vaccine development?
- How does development of a COVID-19 vaccine change (or not change) vaccine related therapeutics investment thesis?
- What are some tips which can be shared with fellow investors and entrepreneurs when it comes to identifying promising vaccine related opportunities to invest in or work on?
- Why the time to start preparing for the next pandemic is now?
This meeting is for informational purposes only. It is not a solicitation or offer to purchase or sell any security, nor should this information be construed as advice for investment decisions.
Private Placements are a high-risk investment. An investment in this offering is speculative and an investor could experience an entire loss of principal. Private investments are highly illiquid and risky and are not suitable for all investors. There is no guarantee that an investment will be profitable or that there will ever be an exit strategy or an opportunity to liquidate the investment. Investments in early-stage private companies should only be part of your overall investment portfolio.
